AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 162 min read$CLOV

Reynoso Jamie L. sold $61K of CLOV

Reynoso Jamie L. (CEO, Medicare Advantage) sold 13,119 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.67 on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Reynoso Jamie L.
Published Jul 16, 2026, 8:50 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 16, 2026, 8:55 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$CLOV
Neutral
high confidence
Mentioned
$CLOV
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVNeutralLow
01

Why it matters

The newest fact is the CEO’s open-market sale of 13,119 shares at $4.6700 on 2026-07-15, filed on 2026-07-16, under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note insider activity, but the 10b5-1 designation and modest transaction value suggest limited incremental trading edge.

03

What to watch

Form 4s often do not capture the full context of insider compensation, tax planning, or concurrent option exercises; the article provides only the sale details.

Relevance 2/10Novelty 3/10Timing: latest Form 4 filed 2026-07-16, covering a sale executed 2026-07-15

Background

The article is a SEC Form 4 insider transaction disclosure for Clover Health Investments Corp. (CLOV).

Company-level read

Ticker impact

$CLOVNeutralHigh confidence
Context

Clover Health CEO Jamie Reynoso sold 13,119 shares on 2026-07-15 at $4.6700, totaling about $61.3K, under a 10b5-1 plan.

Expected impact

Likely minimal immediate price impact; any effect is more sentiment-driven than fundamental.

Evidence & confidence

The filing is a Form 4 insider transaction, but the article specifies a pre-arranged 10b5-1 plan and the disclosed sale size is modest relative to typical market moves.

Market effects

Sector

No clear sector read-through from a single, modest 10b5-1 insider sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale could reflect diversification or liquidity needs rather than bearish expectations, especially given the explicit 10b5-1 plan.

Key entities

  • public_company
    CLOV

    Clover Health Investments Corp. (issuer of the Form 4).

  • insider
    Jamie L. Reynoso

    CEO, Medicare Advantage, who executed the reported open-market sale.

Read at source← All news

Related articles

AUG 7
$CLOVMedAI 8/10

Clover Health Investments Q2 Earnings Call Highlights

Clover Health Investments (CLOV) reported Q2 adjusted EBITDA of $41 million and GAAP net income of $28 million. For the first half of 2026, it posted $81 million adjusted EBITDA and $55 million GAAP net income, with $443 million cash and investments and no debt. The company raised 2026 guidance to $2.92B-$3.0B revenue and $70M-$85M adjusted EBITDA, and discussed cohort maturation and 4.5-star ratings for 2027.

yahoo.com6 min
AUG 6
$METMed

Financial results round-up: MetLife, Prudential, Corebridge, Palomar, Heritage, TWFG, Root and more

A financial results roundup covers multiple insurers and MGAs. MetLife reported Q2 net income of $705m and adjusted EPS $2.43. Prudential posted Q2 net income of $985m and record individual life sales. Corebridge reported a $16m net loss and merger approval. Palomar, Heritage, TWFG, Root, Trupanion and Clover Health also reported Q2 figures and guidance updates.

insurancebusinessmag.com9 min
AUG 5
$CLOVHighAI 9/10

CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV): Results of Operations and Financial Condition

CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2q26exx991xearningsrelease.htm EX-99.1 Document Exhibit 99.1 Clover Health Reports Second Quarter 2026 Results Business Highlights: • Delivered strong second quarter 2026 GAAP Net Income alongside continued market-leading Medicare Advantage membership growth • Improved

SEC EDGAR 8-K6 min
JUL 24
$CLOVMed

What's Fueling Clover Health's Recent Stock Surge

Clover Health (CLOV) shares rose about 7% to $2.39 after UnitedHealth Group (UNH) reported strong Q1 2026 results and raised its full-year adjusted net earnings outlook to over $18.25 per share, lifting sentiment for health insurers. Clover also cited 53% YoY Medicare Advantage membership growth and reiterated 2026 GAAP net income profitability guidance. Analysts maintain a Hold rating and a $2.90 average target.

kavout.com4 min